Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI68319

The deubiquitinase USP44 is a tumor suppressor that protects against chromosome missegregation

Andrew J. Holland and Don W. Cleveland

Find articles by Holland, A. in: JCI | PubMed | Google Scholar

Find articles by Cleveland, D. in: JCI | PubMed | Google Scholar

Published February 1, 2013 - More info

Published in Volume 123, Issue 2 on February 1, 2013
J Clin Invest. 2013;123(2):933–933. https://doi.org/10.1172/JCI68319.
© 2013 The American Society for Clinical Investigation
Published February 1, 2013 - Version history
View PDF

Related article:

The deubiquitinase USP44 is a tumor suppressor that protects against chromosome missegregation
Andrew J. Holland, Don W. Cleveland
Andrew J. Holland, Don W. Cleveland
Commentary

The deubiquitinase USP44 is a tumor suppressor that protects against chromosome missegregation

  • Text
  • PDF
Abstract

The mitotic checkpoint plays an important role in preventing chromosome segregation errors and the production of aneuploid progeny. In this issue, Zhang et al. examine mice and cells lacking the deubiquitinating enzyme USP44. Surprisingly, they find that USP44 prevents chromosome segregation errors through a function independent of its previously identified role in the mitotic checkpoint. Usp44-null animals develop aneuploidy and experience increased rates of tumorigenesis, implicating USP44 as novel tumor suppressor.

Authors

Andrew J. Holland, Don W. Cleveland

×

Original citation: J. Clin. Invest. 2012;122(12):4325–4328. doi:10.1172/JCI66420.

Citation for this erratum: J. Clin. Invest. 2013;123(2):933. doi:10.1172/JCI68319.

Figure 1 was incorrect.

Figure 1

The JCI regrets the error.

Version history
  • Version 1 (February 1, 2013): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts